Overuse of antidepressant drugs for the treatment of depression

CNS Drugs

Volumn 20, Issue 8, 2006, Pages 623-632

  Jureidini, Jon ^a   Tonkin, Anne ^b  

^a WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; FOOD AND DRUG ADMINISTRATION; HEALTH EDUCATION; HEALTH PROGRAM; HEALTH PROMOTION; HUMAN; MEDICAL PRACTICE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW;

AGE FACTORS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DRUG UTILIZATION; HUMANS;

EID: 33746546177     PISSN: 11727047     EISSN: 11727047     Source Type: Journal    
DOI: 10.2165/00023210-200620080-00002     Document Type: Review

References (63)

1. Moncrieff J, Kirsch I. Efficacy of antidepressants in adults. BMJ 2005; 331: 155-7
2. Kirsch I, Moore T, Scoboria A, et al. The emperor's new drugs: an analysis of antidepressant medication data submitted to the US Food and Drug Administration. Prevention & Treatment 2002; 5: article 23 [online]. Available from URL: http://www.journals.apa.org/prevention/volume5/pre0050023a. html [Accessed 2006 Jul 11]
3. Geddes JR, Freemantle N, Mason J, et al. Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression. Cochrane Database Syst Rev 1999; (4): CD001851
4. National Collaborating Centre for Mental Health. Depression: management of depression in primary and secondary care. London: National Institute for Clinical Excellence, 2004
5. Goff VV. Depression: a decade of progress, more to do. NHPF Issue Brief 2002 Nov 22; (786): 1-14
6. Zito JM, Safer DJ, dosReis S, et al. Psychotropic practice patterns for youth; a ten year perspective. Arch Pediatr Adolesc Med 2003; 157: 17-25
7. Hall WD, Mant A, Mitchell PB, et al. Association between antidepressant prescribing and suicide in Australia, 1991-2000: trend analysis. BMJ 2003; 326: 1008-12
8. Ciuna A, Andretta M, Corbari L, et al. Are we going to increase the use of antidepressants up to that of benzodiazepines? Eur J Clin Pharmacol 2004; 60: 629-34
9. Shatin D, Drinkard CR. Ambulatory use of psychotropics by employer-insured children and adolescents in a national managed care organization. Ambul Pediatr 2002; 2: 111-9
10. Rosholm J-U, Gram LF, Isacsson G, et al. Changes in the patter of antidepressant use upon the introduction of the new antidepressants: a prescription database study. Eur J Clin Pharmacol 1997; 52: 205-9
11. Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry 2001; 3: 22-7
12. Haddad PM. Antidepressant discontinuation syndromes. Drug Saf 2001; 24: 183-97
13. Fergusson D, Doucette S, Cranley Glass K, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 2005; 330: 396-402
14. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ 2005; 330 (7488): 385-8
15. Olfson M, Shaffer D, Marcus S, et al. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 2003; 60: 978-82
16. Gibbons R, Hur K, Bhaumik D, et al. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry 2005; 62: 165-72
17. De Leo D, Evans R. International suicide rates and prevention strategies. Washington, DC: Hogrefe & Huber, 2004
18. Delate T, Gelenberg AJ, Simmons VA, et al. Trends in the use of antidepressants in a national sample of commercially insured pediatric patients, 1998-2002. Psychatr Serv 2004; 55: 387-91
19. Sparks JA, Duncan BL. The ethics and science of medicating children. Ethical Hum Psychol Psychiatry 2004; 6: 25-39
20. De Las Cuevas C, Sanz EJ, De La Fuente JA. Variations in antidepressant prescribing practice: clinical need or market influences? Pharmacoepidemiol Drug Saf 2002; 11: 515-22
21. Donohue JM, Berndt ER, Rosenthal M, et al. Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression. Med Care 2004; 42: 1176-85
22. Licht R, Qvitzau S, Allerup P, et al. Validation of the Bech-Rafaelsen Melancholia Scale and the Hamilton Depression Scale in patients with major depression; is the total score a valid measure of illness severity? Acta Psychiatr Scand 2005; 111: 144-9
23. Ellis P, Smith D. Treating depression: the beyondblue guidelines for treating depression in primary care. "Not so much what you do but that you keep doing it". Med J Aust 2002; 176: S77-83
24. Committee on Safety of Medicines. Report of the CSM expert working group on the safety of selective serotonin reuptake inhibitor antidepressants [online]. Available from URL: http://medicines.mhra.gov.uk/ourwork/ monitorsafequalmed/safetymessages/SSRIfinal.pdf, [Accessed 2005 Jul 6]
25. National Collaborating Centre for Mental Health. Depression in children and young people: identification and management in primary, community and secondary care. British Psychological Society, 2005 [online]. Available from URL: http://www.nice.org.uk/pdf/cg028fullguideline.pdf [Accessed 2006 May 15]
26. Martinez C, Rietbrock S, Wise L, et al. Anti-depressant treatment on the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ 2005; 330: 389-95
27. Elkin I, Gibbons RD, Shea MT, et al. Initial severity and differential treatment outcome in the National Institute of Mental Health treatment of Depression Collaborative Research Program. J Consult Clin Psychol 1995; 63: 841-7
28. Barrett JE, Williams Jr JW, Oxman TE, et al. Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18-59 years. J Fam Pract 2001; 50: 405-12
29. Mant A, Rendle V, Hall W, et al. Making new choices about antidepressants in Australia: the long view 1975-2002. Med J Aust 2004; 181: S21-4
30. Rushton JL, Clark SJ, Freed GL. Pediatrician and family physician prescription of selective serotonin reuptake inhibitors. Pediatrics 2000; 105: 82-7
31. Harrison C, Britt H. The rates and management of psychological problems in Australian general practice. Aust N Z J Psychiatry 2004; 38: 781-8
32. Andrews G, Carter GL. What people say about their general practitioners' treatment of anxiety and depression. Med J Aust 2001; 175: S48-51
33. Drug Utilisation Sub-Committee. Australian statistics on medicines 2001-2002. Canberra (ACT): Australian Government, Department of Health and Ageing, 2004
34. Hollinghurst S, Kessler D, Peters T, et al. Opportunity cost of anti-depressant prescribing in England: analysis of routine data. BMJ 2005; 330: 989-1000
35. Andrews G, Sanderson K, Corry J, et al. Using epidemiological data to model efficiency in reducing the burden of depression. J Ment Health Policy Econ 2000; 3: 175-86
36. Katz SJ, Kessler RC, Lin E, et al. Medication management of depression in the United States and Ontario. J Gen Intern Med 1998; 13: 77-85
37. Alonso J, Angermeyer MC, Bernert S, et al. Psychotropic drug utilization in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004; 420: 55-64
38. Pomerantz JM, Finkelstein SN, Berndt ER, et al. Prescriber intent, off-label usage, and early discontinuation of antidepressants: a retrospective physician survey and data analysis. J Clin Psychiatry 2004; 65: 395-404
39. Moynihan R, Cassels A. Selling sickness: how drug companies are turning us all into patients. Sydney: Allen & Unwin, 2005
40. Reed E, Vance A, Luk E, et al. Single and combined psychotropic medication use in a child and adolescent mental health service. Aust N Z J Psychiatry 2004; 38: 204-11
41. Kapczinski F, Lima MS, Souza JS, et al. Antidepressants for generalized anxiety disorder (review). Cochrane Database Syst Rev 2003; (2): CD003592
42. Algulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder; twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 2001; 179: 15-22
43. Linjakumpu T, Hartikainen S, Klaukka T, et al. Psychotropics among the home-dwelling elderly: increasing trends. Int J Geriatr Psychiatry 2002; 17: 874-83
44. Mamdani M, Rapoport M, Shulman KI, et al. Mental health-related drug utilization among older adults; prevalence, trends and costs. Am J Geratr Psychiatry 2005; 13: 892-900
45. Spore DL, Mor V, Larrat P, et al. Regulatory environment and psychotropic use in board-and-care facilities: results of a 10-state study. J Gerontol A Biol Sci Med Sci 1996; 51: M131-41
46. Furniss L, Burns A, Craig SKL, et al. Effects of a pharmacist's medication review in nursing homes: randomised controlled trial. Br J Psychiatry 2000; 176: 563-7
47. Chu L, Schnelle JF, Osterweil D. Prescription analgesic and antidepressant utilization and cost among elderly Medicaid beneficiaries before and after nursing home admission. J Am Med Dir Assoc 2004; 5: 75-81
48. Snowdon J, Burgess E, Vaughan R, et al. Use of antidepressants, and the prevalence of depression and cognitive impairment in Sydney nursing homes. Int J Geratric Psychiatry 1996; 11: 599-606
49. Hanlon JT, Schmader KE, Ruby CM, et al. Suboptimal prescribing in older inpatients and outpatients. J Am Geriatr Soc 2001; 49: 200-9
50. Williams JW, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000; 132: 743-56
51. Burrows AB, Salzman C, Satlin A, et al. A randomized, placebo-controlled trial of paroxetine in nursing home residents with non-major depression. Depress Anxiety 2002; 15: 102-10
52. Bourin M. Use of paroxetine for the treatment of depression and anxiety disorders in the elderly: a review. Hum Psychopharmacol 2003; 18: 185-90
53. Jureidini J, Doecke C, Mansfield P, et al. Efficacy and safety of antidepressants for children and adolescents. BMJ 2004; 328: 879-83
54. Brent D. Antidepressants and pediatric depression: the risk of doing nothing. N Engl J Med 2004; 351: 1598-601
55. Tonkin A, Jureidini J. Wishful thinking: antidepressant drugs in childhood depression. Br J Psychiatry 2005; 187: 304-5
56. Lyons JS, MacIntyre JC, Lee ME, et al. Psychotropic medications prescribing patterns for children and adolescents in New York's public mental health system. Community Ment Health J 2004; 40: 101-18
57. National Collaborating Centre for Mental Health. Schizophrenia: full national clinical guideline on core interventions in primary and secondary care. London: Gaskell and British Psychological Society, 2003
58. Gilberg K, Laouri S, Wade S, et al. Analysis of medication use patterns: apparent overuse of antibiotics and underuse of prescription drugs for asthma, depression and CHF. J Managed Care Pharm 2003; 3: 232-7
59. Tierney R, Melfi CA, Signa W, et al. Antidepressant use and use patterns in naturalistic settings. Drug Benefit Trends 2000; 6: 7-12
60. Healy D, Aldred G. Anti-depressant drug use and the risk of suicide. Int Rev Psychiatry 2005; 17: 163-72
61. Kessler R, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R). JAMA 2003; 289: 3095-105
62. Spijker J, deGraaf R, Bijl R, et al. Duration of major depressive episodes in the general population: results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Br J Psychiatry 2002; 181: 208-13
63. Thomson O'Brien MA, Oxman AD, Davis DA, et al. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2000; (2): CD000409